We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

428 hedge funds and large institutions have $3.74B invested in Teva Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 132 increasing their positions, 137 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more funds holding in top 10

Funds holding in top 10: 11 → 13 (+2)

11% more call options, than puts

Call options by funds: $162M | Put options by funds: $145M

4% less repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 137

2% less funds holding

Funds holding: 438 → 428 (-10)

6.22% less ownership

Funds ownership: 50.44% → 44.22% (-6.2%)

15% less first-time investments, than exits

New positions opened: 51 | Existing positions closed: 60

24% less capital invested

Capital invested by funds: $4.95B → $3.74B (-$1.21B)

Holders
428
Holders Change
-10
Holders Change %
-2.28%
% of All Funds
6.72%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.2%
New
51
Increased
132
Reduced
137
Closed
60
Calls
$162M
Puts
$145M
Net Calls
+$16.5M
Net Calls Change
+$50.3M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$115M
2
CI
Clal Insurance
Israel
+$104M
3
SPC
Slate Path Capital
New York
+$101M
4
PF
Phoenix Financial
Israel
+$93.8M
5
Norges Bank
Norges Bank
Norway
+$63.6M

Top Sellers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
-$731M
2
Capital World Investors
Capital World Investors
California
-$410M
3
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$189M
4
Citadel Advisors
Citadel Advisors
Florida
-$41.1M
5
Citigroup
Citigroup
New York
-$32.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
101
Zurich Cantonal Bank
Switzerland
$2.84M +$2.66K +328 +0.1%
Teacher Retirement System of Texas
102
Teacher Retirement System of Texas
Texas
$2.75M +$579K +71,424 +24%
TC
103
TwinBeech Capital
New York
$2.72M +$2.93M +360,843 New
Canada Life
104
Canada Life
Manitoba, Canada
$2.69M -$1.18M -145,805 -29%
CM
105
Caption Management
Oklahoma
$2.68M +$2.89M +355,990 New
Nomura Asset Management
106
Nomura Asset Management
Japan
$2.68M +$92.4K +11,400 +3%
PAMS
107
Pictet Asset Management (Switzerland)
Switzerland
$2.64M -$109K -13,500 -4%
State of Wisconsin Investment Board
108
State of Wisconsin Investment Board
Wisconsin
$2.53M -$108K -13,300 -4%
SO
109
STRS Ohio
Ohio
$2.53M +$1.15K +142 +0%
WMSA
110
Weiss Multi-Strategy Advisers
New York
$2.52M +$1.33M +163,639 +96%
FAF
111
Fjarde Ap-fonden
Sweden
$2.5M +$1.42M +174,700 +111%
Royal Bank of Canada
112
Royal Bank of Canada
Ontario, Canada
$2.48M +$507K +62,522 +23%
QT
113
Quantbot Technologies
New York
$2.38M +$2.32M +285,891 +941%
DA
114
Duality Advisers
Florida
$2.38M +$169K +20,891 +7%
Squarepoint
115
Squarepoint
New York
$2.36M +$2.33M +287,547 +1,111%
AS
116
Altshuler Shaham
Israel
$2.35M -$44.7K -5,517 -2%
HSBC Holdings
117
HSBC Holdings
United Kingdom
$2.35M +$34.4K +4,237 +1%
DA
118
DSC Advisors
Illinois
$2.33M +$1.05M +130,000 +72%
PCM
119
Patient Capital Management
Maryland
$2.3M -$2.59M -319,946 -51%
Wells Fargo
120
Wells Fargo
California
$2.26M -$1.37M -169,034 -36%
SFM
121
Spartan Fund Management
Canada
$2.16M +$20.1K +2,477 +2%
Public Employees Retirement Association of Colorado
122
Public Employees Retirement Association of Colorado
Colorado
$2.04M -$234K -28,900 -10%
MG
123
Marex Group
$2.03M +$1.25M +153,561 +132%
RhumbLine Advisers
124
RhumbLine Advisers
Massachusetts
$2M +$2.15M +265,564 New
SCM
125
Saba Capital Management
New York
$1.9M +$343K +42,360 +20%
3 4
5
6 7

TEVA Hedge Fund Activity: Q2 2023 in Review

428 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2023, worth a combined $3.74B — down 24% from $4.95B a quarter earlier.

Sellers outnumbered buyers: 60 funds closed out of TEVA and 51 opened new positions — a net loss of 9 holders — while 137 trimmed existing stakes and 132 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $115M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $731M sold.

  • 428 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2023, down from 438 in Q1 2023.
  • Funds reported $3.74B of Teva Pharmaceuticals stock for Q2 2023, down 24% quarter-over-quarter.
  • 51 funds opened new Teva Pharmaceuticals positions in Q2 2023 and 60 closed out, a net change of -9 holders.
  • The largest Teva Pharmaceuticals buyer in Q2 2023 was Rubric Capital Management (New York), an estimated $115M added.
  • The largest Teva Pharmaceuticals seller in Q2 2023 was Capital Research Global Investors, an estimated $731M sold.

Based on aggregated 13F filings for Q2 2023.